FELDENE

10 MG · capsule · box 20 capsules

Historical reference: this presentation is not marketed, withdrawn or suspended according to the source. Its listed price does not establish availability.

Reference dated : 2026-10-01. Confirm price and availability with a pharmacist.

Public price

41,40 MAD

What is this medicine?

French reference leaflet: PIROXICAM BIOGARAN 10 mg, gélule. Confirm indications in Morocco with a pharmacist.

Pharmacotherapeutic class: non-steroidal anti-inflammatory drugs, ATC code: M01AC01. Before prescribing piroxicam to you, your doctor must evaluate the benefits that this medicine is likely to bring you compared to the risk incurred of developing adverse effects. Due to this treatment, your doctor may need to have you undergo periodic medical examinations and will then be required to indicate the frequency at which you must be examined. PIROXICAM BIOGARAN is used to relieve certain symptoms of osteoarthritis (degenerative disease of the joints), rheumatoid arthritis, and ankylosing spondylitis (rheumatological condition of the spine), such as swelling, stiffness, and joint pain. It does not cure osteoarthritis and will only relieve it for as long as you continue to take it. Your doctor will only be required to prescribe piroxicam to you in the event of symptoms insufficiently relieved with other non-steroidal anti-inflammatory drugs (NSAIDs).

Full clinical reference

Additional sections are available in French. Read the original document; the information concerns the French reference product.

Uses

Piroxicam is indicated in the symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis. Due to its tolerability profile (see sections 4.2, 4.3 and 4.4), piroxicam must not be used as first-line treatment when NSAID treatment is indicated.

The decision to prescribe a specialty containing piroxicam must be based on the assessment of all specific risks for each patient (see sections 4.3 and 4.4).

Driving

Warn patients of the possible onset of dizziness and drowsiness.

Adverse effects

Clinical studies and epidemiological data suggest that the use of certain NSAIDs (especially when used at high doses and for a long duration) may be associated with a slight increase in the risk of an arterial thrombotic event (for example, myocardial infarction or stroke) (see section 4.4).

The most frequently observed adverse effects are gastrointestinal in nature. Peptic ulcers, perforations or gastrointestinal haemorrhages, sometimes fatal, may occur, particularly in the elderly (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, ulcerative stomatitis, abdominal pain, melaena, haematemesis, exacerbation of ulcerative colitis or Crohn's disease (see section 4.4) have been reported following the administration of NSAIDs. Less frequently, gastritis has been observed.

Oedema, hypertension and heart failure have been reported in association with NSAID treatment.

The table below presents the adverse effects by medical discipline and by frequency. Within each frequency group, the adverse effects are classified in descending order of severity.

Organ system class	Common (≥ 1/100 and < 1/10)	Uncommon (≥ 1/1000 and < 1/100)	Frequency unknown (cannot be estimated on the basis of available data)
Blood and lymphatic system disorders			Aplastic anaemia* (Bone marrow aplasia) and Haemolytic anaemia* Eosinophilia* Leucopenia* Thrombocytopenia*
Immune system disorders			Anaphylaxis* Serum sickness*
Metabolism and nutrition disorders	Anorexia		Hyperglycaemia* Hypoglycaemia* Water retention* Water and sodium retention* Hyperkalaemia*
Nervous system disorders	Headache, Dizziness sensations, Somnolence, Vertigo		Aseptic meningitis* Paresthesia*
Eye disorders		Blurred vision	Eye irritation* Eye swelling*
Ear and labyrinth disorders	Tinnitus		Decreased auditory acuity*
Cardiac disorders		Palpitations
Vascular disorders			Vasculitis* Hypertension*
Respiratory, thoracic and mediastinal disorders			Bronchospasm* Dyspnoea* Epistaxis* Asthma attack*
Gastrointestinal disorders	Epigastric heaviness, Nausea, Constipation, Abdominal discomfort, Flatulence, Abdominal pain, Diarrhoea, Vomiting, Indigestion	Stomatitis	Perforations* Ulcers* Pancreatitis* Gastro-intestinal bleeding (including haematemesis and melaena)* Gastritis*
Hepatobiliary disorders			Fatal hepatitis* Severe hepatitis* Jaundice*
Skin and subcutaneous tissue disorders	Skin rash, Pruritus		Quincke's oedema* (Angio-oedema) Stevens-Johnson syndrome Toxic epidermal necrolysis (Lyell's syndrome)* DRESS syndrome* Bullous skin reactions* Exfoliative dermatitis* Erythema multiforme* Photosensibilisation* Fixed pigment erythema* Non-thrombocytopenic purpura (Schönlein-Henoch)* Onycholysis* Worsening of chronic urticaria* Alopecia*
Renal and urinary disorders			Acute renal failure (ARF) functional* Nephrotic syndrome* Glomerulonephritis* Interstitial nephritis* Papillary necrosis* Acute tubular necrosis*
Reproductive system and breast disorders			Decreased female fertility*
General disorders and administration site abnormalities	Edema, notably of the lower limbs		Malaise*
Investigations	Reversible elevation of blood urea nitrogen elevation transient or reversible of serum transaminases decrease in hemoglobin and hematocrit levels not associated with obvious gastrointestinal bleeding	Reversible elevation of serum creatinine	Positive antinuclear antibody test* transient or reversible elevation of bilirubin* decrease in platelet aggregation and prolongation of bleeding time*
a Aplastic anemia is a form of bone marrow aplasia. * Adverse effects identified after marketing.

Reporting of suspected adverse effects

Reporting of suspected adverse effects after medicinal product authorization is important. It allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare professionals report any suspected adverse effect via the national reporting system: French National Agency for Medicines and Health Products Safety (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr/

Read the French reference

Hospital price

25,90 MAD

Commercial status

Non Commercialisé

Type

Originator

Therapeutic class

ANTALGIQUES-ANALGESIQUES-ANTIPYRETIQUES-ANTI-INFLAMMATOIRES-ANTISPASMODIQUES

References and update dates

AMMPS — catalogue marocain officiel · 2026-10-01

Product and price reference

Base de données publique des médicaments (France) · 2026-09-29 · Licence Ouverte

Read medical reference

This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.

Price history

Reference price recorded since 2026-10-01: 41,40 MAD

Reference price recorded since 2017-12-18: 44,30 MAD

Same ingredient, strength and form

This grouping does not establish interchangeability.

Other strengths and forms

Routes and instructions may differ.

FELDENE

What is this medicine?

Full clinical reference

Price history

Referenced presentations and strengths

FELDENE

FELDENE

FELDENE

FELDENE

FELDENE

FELDENE

FELDENE

FELDENE

FELDENE

FELDENE

FELDENE

FELDENE

Same ingredient, strength and form

RIACEN

SOLICAM

SOLICAM

SOLICAM

SOLICAM

Other strengths and forms